EDGE Medical-B Shares Surge Over 13% on Australian Market Entry and Robot Approvals

Stock News07-23

Shares of EDGE MEDICAL-B (02675) experienced a significant surge of over 13% during the morning trading session.

As of the latest update, the stock was up 13.37% to HK$41.38, with a trading turnover of HK$21.79 million.

The catalyst for this upward movement is recent company news regarding its expansion into the Australian market.

According to an official announcement, the company's self-developed surgical robot systems have successfully received regulatory approval from Australia's Therapeutic Goods Administration.

The approved products include the Edge Multi-Port Laparoscopic Surgical Robot MP1000, the Edge Single-Port Laparoscopic Surgical Robot SP1000, and the integrated Edge Multi/Single-Port Surgical Robot Super System MSP2000.

All three platforms have been officially listed on the Australian Register of Therapeutic Goods.

These approved robotic systems are indicated for endoscopic surgical procedures across multiple specialties, including urology, gynecology, general surgery, and thoracic surgery.

This regulatory milestone signifies formal market access for the company's comprehensive portfolio of multi-port, single-port, and integrated surgical robot platforms in Australia.

It establishes a crucial foundation for the company's strategy to further develop its presence in the Australian and broader Asia-Pacific markets.

Furthermore, this achievement represents a significant step in advancing the global clinical application of domestically developed, high-end surgical robotic technology.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192994502?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192994502","market":"nz","top_or_hot":-1,"title":"EDGE Medical-B Shares Surge Over 13% on Australian Market Entry and Robot Approvals","media":"Stock News","content":"<p>Shares of <b>EDGE MEDICAL-B</b> (<b>02675</b>) experienced a significant surge of over 13% during the morning trading session.<br><br>As of the latest update, the stock was up 13.37% to HK$41.38, with a trading turnover of HK$21.79 million.<br><br>The catalyst for this upward movement is recent company news regarding its expansion into the Australian market.<br><br>According to an official announcement, the company's self-developed surgical robot systems have successfully received regulatory approval from Australia's Therapeutic Goods Administration.<br><br>The approved products include the Edge Multi-Port Laparoscopic Surgical Robot MP1000, the Edge Single-Port Laparoscopic Surgical Robot SP1000, and the integrated Edge Multi/Single-Port Surgical Robot Super System MSP2000.<br><br>All three platforms have been officially listed on the Australian Register of Therapeutic Goods.<br><br>These approved robotic systems are indicated for endoscopic surgical procedures across multiple specialties, including urology, gynecology, general surgery, and thoracic surgery.<br><br>This regulatory milestone signifies formal market access for the company's comprehensive portfolio of multi-port, single-port, and integrated surgical robot platforms in Australia.<br><br>It establishes a crucial foundation for the company's strategy to further develop its presence in the Australian and broader Asia-Pacific markets.<br><br>Furthermore, this achievement represents a significant step in advancing the global clinical application of domestically developed, high-end surgical robotic technology.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EDGE Medical-B Shares Surge Over 13% on Australian Market Entry and Robot Approvals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEDGE Medical-B Shares Surge Over 13% on Australian Market Entry and Robot Approvals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-23 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>EDGE MEDICAL-B</b> (<b>02675</b>) experienced a significant surge of over 13% during the morning trading session.<br><br>As of the latest update, the stock was up 13.37% to HK$41.38, with a trading turnover of HK$21.79 million.<br><br>The catalyst for this upward movement is recent company news regarding its expansion into the Australian market.<br><br>According to an official announcement, the company's self-developed surgical robot systems have successfully received regulatory approval from Australia's Therapeutic Goods Administration.<br><br>The approved products include the Edge Multi-Port Laparoscopic Surgical Robot MP1000, the Edge Single-Port Laparoscopic Surgical Robot SP1000, and the integrated Edge Multi/Single-Port Surgical Robot Super System MSP2000.<br><br>All three platforms have been officially listed on the Australian Register of Therapeutic Goods.<br><br>These approved robotic systems are indicated for endoscopic surgical procedures across multiple specialties, including urology, gynecology, general surgery, and thoracic surgery.<br><br>This regulatory milestone signifies formal market access for the company's comprehensive portfolio of multi-port, single-port, and integrated surgical robot platforms in Australia.<br><br>It establishes a crucial foundation for the company's strategy to further develop its presence in the Australian and broader Asia-Pacific markets.<br><br>Furthermore, this achievement represents a significant step in advancing the global clinical application of domestically developed, high-end surgical robotic technology.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"","article_id":"1192994502","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192994502","pubTimestamp":1784771303,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of EDGE MEDICAL-B (02675) experienced a significant surge of over 13% during the morning trading session.As of the latest update, the stock was up 13.37% to HK$41.38, with a trading turnover...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","02675":"精锋医疗-B","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","BK4582":"ESG ETF-MSCI","HTEC":"ROBO Global Healthcare Technology and Innovation ETF","KCAI":"KraneShares China Alpha Index ETF","MDEV":"First Trust Indxx Medical Devices ETF","EWA":"澳大利亚ETF-iShares MSCI"},"translate_title":"由于澳大利亚市场进入和机器人批准，EDGE Medical-B 股价飙升超过 13%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HTEC":1,"MDEV":1,"EWA":1,"02675":1,"KCAI":1,"VXUS":1},"content_text":"Shares of EDGE MEDICAL-B (02675) experienced a significant surge of over 13% during the morning trading session.As of the latest update, the stock was up 13.37% to HK$41.38, with a trading turnover of HK$21.79 million.The catalyst for this upward movement is recent company news regarding its expansion into the Australian market.According to an official announcement, the company's self-developed surgical robot systems have successfully received regulatory approval from Australia's Therapeutic Goods Administration.The approved products include the Edge Multi-Port Laparoscopic Surgical Robot MP1000, the Edge Single-Port Laparoscopic Surgical Robot SP1000, and the integrated Edge Multi/Single-Port Surgical Robot Super System MSP2000.All three platforms have been officially listed on the Australian Register of Therapeutic Goods.These approved robotic systems are indicated for endoscopic surgical procedures across multiple specialties, including urology, gynecology, general surgery, and thoracic surgery.This regulatory milestone signifies formal market access for the company's comprehensive portfolio of multi-port, single-port, and integrated surgical robot platforms in Australia.It establishes a crucial foundation for the company's strategy to further develop its presence in the Australian and broader Asia-Pacific markets.Furthermore, this achievement represents a significant step in advancing the global clinical application of domestically developed, high-end surgical robotic technology.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192994502","isCrawlerRequest":true}